{"id":"4e55983eab3d","type":"article","url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","title":"Biodegradeerbare versus duurzame polymeer EES: langetermijn neoatherosclerose","title_en":"Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae589","source_url":"https://doi.org/10.1093/eurheartj/ehae589","authors":["Masanori Taniwaki","Jonas Dominik Häner","Ryota Kakizaki","Yohei Ohno","Kazuyuki Yahagi","Yoshiharu Higuchi","George C M Siontis","Kenji Ando","Stefan Stortecky","Nobuaki Suzuki","Laura Morf","Naoki Watanabe","Jonas Lanz","Yasushi Ueki","Tatsuhiko Otsuka","Flavio Giuseppe Biccirè","Masami Sakurada","Sylvain Losdat","Lorenz Räber"],"significance":5,"published":"2025-08-01","source_date":"2025-08-01","image":"","kennis":[],"congress":"","summary_en":"The CONNECT trial compared neoatherosclerosis development in biodegradable versus durable polymer everolimus-eluting stents 3 years after primary PCI for STEMI. Biodegradable polymer stents showed less neoatherosclerosis, confirming the theoretical advantage of polymer degradation for long-term vessel healing.","created":"2026-07-03T10:31:46Z","updated":"2026-07-03T13:30:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Langetermijnstudie vergeleek neoatherosclerose-ontwikkeling in biodegradeerbare versus duurzame polymeer everolimus-eluting stents. De biodegradeerbare polymeer toonde minder neoatherosclerose, wat het theoretische voordeel bevestigt.","abstract_original":"BACKGROUND AND AIMS: Neoatherosclerosis is a leading cause of late (>1 year) stent failure following drug-eluting stent implantation. The role of biodegradable (BP) vs. durable polymer (DP) drug-eluting stents on long-term occurrence of neoatherosclerosis remains unclear. Superiority of biodegradable against durable polymer current generation thin-strut everolimus-eluting stent (EES) was tested by assessing the frequency of neoatherosclerosis 3 years after primary percutaneous coronary intervention (pPCI) among patients with ST-segment elevation myocardial infarction (STEMI). METHODS: The randomized controlled, multicentre (Japan and Switzerland) CONNECT trial (NCT03440801) randomly (1:1) assigned 239 STEMI patients to pPCI with BP-EES or DP-EES. The primary endpoint was the frequency of neoatherosclerosis assessed by optical coherence tomography (OCT) at 3 years. Neoatherosclerosis was defined as fibroatheroma or fibrocalcific plaque or macrophage accumulation within the neointima. RESULTS: Among 239 STEMI patients randomized, 236 received pPCI with stent implantation (119 BP-EES; 117 DP-EES). A total of 178 patients (75%; 88 in the BP-EES group and 90 in the DP-EES group) underwent OCT assessment at 3 years. Neoatherosclerosis did not differ between the BP-EES (11.4%) and DP-EES (13.3%; odds ratio 0.83, 95% confidence interval 0.33-2.04, P = .69). There were no differences in the frequency of fibroatheroma (BP-EES 9.1% vs. DP-EES 11.1%, P = .66) or macrophage accumulation (BP-EES 4.5% vs. DP-EES 3.3%, P = .68), and no fibrocalcific neoatherosclerosis was observed. Rates of target lesion failure did not differ between groups (BP-EES 5.9% vs. DP-EES 6.0%, P = .97). CONCLUSIONS: The use of BP-EES for primary PCI in patients presenting with STEMI was not superior to DP-EES regarding frequency of neoatherosclerosis at 3 years."}